经济观察网2026年1月22日，利君股份（002651）发布2025年度业绩预告，预计2025年净利润4800万元 至6600万元，同比下降45.05%至60.03%；扣除非经常性损益后的净利润4100万元至5900万元，同比下 降49.61%至64.98%。 ...

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

证券日报网讯1月22日，利君股份（002651）发布2025年度业绩预告称，公司预计2025年度归属于上市 公司股东的净利润为4，800万元–6，600万元，比上年同期下降45.05%-60.03%。 ...

利君股份（002651）(002651.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润4800 万元–6600万元，同比下降45.05%-60.03%;扣除非经常性损益后的净利润4100万元–5900万元，同比下降 49.61%-64.98%。 ...

智通财经APP讯，利君股份(002651.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 4800万元–6600万元，同比下降45.05%-60.03%;扣除非经常性损益后的净利润4100万元–5900万元，同比 下降49.61%-64.98%。 ...

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

每经AI快讯，1月22日，利君股份（002651）(002651.SZ)发布2025年度业绩预告，预计归属于上市公司 股东的净利润为4,800万元–6,600万元，比上年同期下降45.05%–60.03%。报告期内，公司粉磨系统及配 套设备制造业务受行业市场需求影响，订单下降，部分项目未交付结算，同时海外拓展费用增加，导致 净利润下滑。 ...

利君股份公告，预计2025年度净利润为4800万元– 6600万元，同比下降45.05%-60.03%。本报告期，公 司业绩变化主要有两方面原因：1、公司粉磨系统及其配套设备制造业务水泥用辊压机及配套受所属行 业市场需求影响竞争加剧订单下降，以及矿山用高压辊磨机部分项目尚未实现交付和结算，对应收入尚 未确认，致使板块净利润相应下降；2、公司为拓展粉磨系统及其配套设备制造业务海外市场，费用较 上期增加，致使净利润相应下降。 ...

证券代码：002651 证券简称：利君股份 公告编号：2026-01 成都利君实业股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 本报告期，公司业绩变化主要有两方面原因：1、公司粉磨系统及其配套设备制造 业务水泥用辊压机及配套受所属行业市场需求影响竞争加剧订单下降，以及矿山用高压 辊磨机部分项目尚未实现交付和结算，对应收入尚未确认，致使板块净利润相应下降； 2、公司为拓展粉磨系统及其配套设备制造业务海外市场，费用较上期增加，致使净利 润相应下降。 综上，经公司财务部门测算2025年度归属于上市公司股东的净利润预计在4,800万 元至6,600万元之间，较上年同期下降45.05%-60.03%。 2025年1月1日至2025年12月31日 （二）业绩预告情况 □扭亏为盈 □同向上升 √同向下降 | 项 | 目 | | | 本报告期 | | | | 上年同期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东 ...

1月9日，成都利君实业股份有限公司在投资者互动平台上表示，公司全资子公司德坤航空主营航空航天零部件制造业务， 目前该公司生产经营一切正常。同日，贵州航天电器股份有限公司（以下简称"航天电器"）回复投资者称，商业航天是公司重 点拓展的新业务，目前相关产品订货占公司总收入比例较小。 值得关注的是，近期也有多家上市公司发布公告提示交易风险。 1月9日，航天时代电子技术股份有限公司发布股票交易异常波动公告，提示公司基本面未发生重大变化，存在市场情绪过 热及非理性炒作的情形，公司股票存在短期大幅下跌的风险，交易风险极大；提示投资者注意交易风险，理性决策，审慎投 资。1月8日晚间，航天电器发布公告，明确近期公司生产经营情况正常，内外部经营环境未发生重大变化，提示投资者理性投 资，注意投资风险。 "政策红利持续释放，向资本市场和产业界传递出明确信号，极大提振了社会资本的投资信心，持续引导'耐心资本'从观望 转向实质性投入。"中关村物联网产业联盟副秘书长袁帅向《证券日报》记者表示。 受政策利好影响，我国商业航天市场规模不断扩容，产业发展驶入快车道。中商产业研究院发布的《2025—2030年中国商 业航天行业深度分析及发展前景 ...